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ABSTRACT 
 
Objectives 
To describe the “Resuscitation with Pre-HospItaL bLood products” trial (RePHILL) - a 
multi-centre randomised controlled trial of pre-hospital blood product (PHBP) 
administration versus standard care for traumatic haemorrhage. 
 
Background 
PHBP are increasingly used for pre-hospital trauma resuscitation despite a lack of 
robust evidence demonstrating superiority over crystalloids. Provision of PHBP 
carries additional logistical and regulatory implications, and requires a sustainable 
supply of universal blood components.  
 
Methods 
RePHILL is a multi-centre, two-arm, parallel group, open-label, phase III randomised 
controlled trial currently underway in the UK. Patients attended by a pre-hospital 
emergency medical team, with traumatic injury and hypotension (systolic blood 
pressure<90mmHg or absent radial pulse) believed to be due to traumatic 
haemorrhage are eligible. Exclusion criteria include: age<16 years, blood product 
receipt on scene prior to randomisation, Advanced Medical Directive forbidding blood 
product administration, pregnancy, isolated head injury and prisoners. 490 patients 
will be recruited in a 1:1 ratio to receive either the intervention (up to two units of red 
blood cells and two units of lyophilised plasma) or the control (up to 4 boluses of 
250ml 0.9% saline). The primary outcome measure is a composite of failure to 
achieve lactate clearance of ≥20% per hour over the first two hours after 
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randomisation and all-cause mortality between recruitment and discharge from the 
primary receiving facility to non-acute care. Secondary outcomes include pre-
hospital time, coagulation indices, in-hospital transfusion requirements and 
morbidity. 
 
Conclusions 
RePHILL will provide high quality evidence regarding the efficacy and safety of 
PHBP resuscitation for trauma. 
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INTRODUCTION 
 
The last two decades have seen great changes in trauma resuscitation 
practice (Holcomb, 2017). Hospital treatment of haemorrhagic shock increasingly 
emphasises early use of blood products and minimisation of crystalloids – previously 
the mainstay of pre-hospital and in-hospital volume replacement. Major 
haemorrhage protocols have been widely adopted to deliver plasma in high ratios to 
red blood cells (RBC) early in resuscitation. Improved survival from such strategies 
has been reported in both military and civilian settings (Bhangu et al., 2013; Murad et 
al., 2010). Delivery may nonetheless require significant performance improvement; 
data published in 2016 showed that only 2% of UK trauma haemorrhage patients 
received “optimum” plasma:RBC ratios (≥1:2), with average delay to first plasma 
transfusion exceeding one hour (Stanworth et al., 2016). 
 
Pre-hospital blood product (PHBP) administration is a key element of “Remote 
Damage Control Resuscitation” (Jenkins et al., 2014a). It reduces time-to-transfusion 
and may improve survival. Various PHBP combinations have been deployed by pre-
hospital emergency medical (PHEM) providers (Dalton, 1993; Glassberg et al., 2013; 
O'Reilly et al., 2014a; Sunde et al., 2015; Wales Air Ambulance, 2015; Weaver et al., 
2013; Zielinski et al., 2017). Although a biological case for the superiority of PHBP 
resuscitation can be made (Holcomb et al., 2015a), our group’s systematic review of 
the clinical literature reported that the majority of evidence was of “very low quality” 
(as defined by the Grading of Recommendations, Assessment, Development and 
Evaluations (GRADE) criteria (Kerwin et al., 2012)) from which no reliable 
conclusions could be drawn (Smith et al., 2016). Recently released UK national 
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guidelines for trauma management (National Institute for Health and Clinical 
Excellence, 2016) did not examine any pre-hospital transfusion studies. Instead, pre-
hospital guidance was extrapolated from one in-hospital cohort study of patients 
receiving 10u RBC in the first 24h after admission (Neal et al., 2012).  
 
“A Multi-Centre Randomised Controlled Trial of Pre-Hospital Blood Product 
Administration versus Standard Care for Traumatic Haemorrhage” (abbreviated title: 
“Resuscitation with Pre-HospItaL bLood products” or “RePHILL”) is a randomised 
controlled trial (RCT) which will investigate the hypothesis that pre-hospital 
administration of up to two units each of RBC and lyophilised (freeze-dried) plasma 
(LP) will improve tissue perfusion (as measured by lactate clearance) and reduce 
mortality in trauma patients with haemorrhagic shock compared to the current 
practice of the majority of UK PHEM services of crystalloid resuscitation. 
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MATERIALS AND METHODS 
 
Trial Design 
This study is a multi-centre, two-arm, parallel group, open-label, interventional phase 
III RCT of 490 patients. An internal pilot phase was included to validate trial logistics. 
The trial schema is shown in figure 1. This protocol conforms to the SPIRIT 
guidelines (Chan et al., 2013). The pilot phase began recruitment in December 2016, 
with approval to continue into the main trial received in June 2017. Recruitment is 
expected to continue until 2020. 
 
Trial Objectives 
Primary Objective 
The principle objective of RePHILL is to investigate the clinical effectiveness of 
PHBP resuscitation compared with the current standard care of restricted crystalloid 
based resuscitation in participants suffering from major traumatic haemorrhage. 
 
Secondary Objectives 
To test the hypotheses that, compared to standard care, PHBP resuscitation: 
a. improves blood pressure, heart rate and capillary oxygenation on arrival to the 
Emergency Department (ED). 
b. does not prolong pre-hospital time. 
c. reduces pre-hospital fluid requirements. 
d. reduces in-hospital transfusion requirements. 
e. reduces trauma-induced coagulopathy. 
f. preserves platelet function. 
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g. does not lead to a greater incidence of transfusion-related complications, 
particularly acute respiratory distress syndrome (ARDs). 
h. does not lead to significant blood product wastage. 
 
Outcomes 
Primary Outcome 
The primary outcome is a composite measure consisting of episode mortality (death 
from all causes between trial entry and discharge from the primary receiving facility 
to non-acute care) and failure to achieve lactate clearance of ≥20%/hr over the first 
two hours after randomisation. Regnier et al (2012) studied this endpoint, reporting 
that mortality amongst such patients is approximately 20%, similar to the 23% 
mortality in trauma patients with a comparable degree of hypotension to those 
eligible for RePHILL (Hasler et al., 2011, 2012). Lactate clearance is thus a clinically 
meaningful biochemical predictor of outcome, but subject to minimal confounding 
from in-hospital interventions. Table 1 describes calculation of lactate clearance. 
 
Secondary Outcomes 
Secondary outcomes are listed in Table 2. 
 
Sample Size Calculation 
Although no definitive data exists on this composite outcome, observational studies 
suggest potentially dramatic reductions in mortality from civilian pre-hospital 
RBC (Brown et al., 2015b) and military pre-hospital RBC combined with thawed 
plasma (O'Reilly et al., 2014b). Following consultation with experts in pre-hospital 
trauma resuscitation, it is considered that an absolute reduction of 10% in the 
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proportion of patients experiencing one of the component primary outcomes is 
clinically meaningful and is an appropriate effect size upon which to base the power 
calculation. 
 
To detect an absolute difference of 10% between groups in the proportion of patients 
experiencing either component of the primary outcome (i.e. from 20% in the standard 
care group to 10% in the group receiving PHBP) using the method of difference 
between proportions (2-sided Fisher’s Exact Test) with 80% power, and a type 1 
error rate of 5% (i.e. α=0.05), requires 438 participants. Allowing and adjusting for a 
10% loss to follow-up, 490 participants are required. 
 
Setting 
The study takes place in three regional major trauma networks in England (West 
Midlands, East Midlands, East of England). These networks consist of integrated 
National Health Service (NHS) ambulance services and PHEM teams, supported by 
six charity-funded air ambulances, and NHS hospitals designated as Major Trauma 
Centres and Trauma Units. PHEM teams consist of a Critical Care Paramedic and a 
doctor at a minimum level of a specialty registrar sub-specialising in PHEM. Patients 
will be identified and entered into the trial by the relevant PHEM doctors. 
 
Eligibility criteria 
Entry criteria for RePHILL participants are listed in Table 3. 
 
 
Trial Interventions 
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All trial-specific processes were designed to minimise any prolongation of pre-
hospital time.  
 
Experimental Intervention 
The trial intervention is up to two units of RBCs (blood group O RhD negative, Kell 
negative) and two units of LyoPlas N-w, blood groups A or AB (DRK-
Blutspendedienst West, Ratingen, Germany) (see Source of LP), delivered as single-
unit boluses in the following sequence: one unit RBC, one unit LyoPlas N-w, one unit 
RBC, one unit LyoPlas N-w). This sequence was chosen as the most efficient, 
allowing the first unit of RBC to be delivered while LyoPlas N-w is being 
reconstituted. Both LyoPlas N-w units in single intervention are the same blood 
group. 
 
Control Intervention 
The control intervention is up to four 250ml boluses of 0.9% saline. This was chosen 
because it is the most common crystalloid used by the PHEM services in the UK for 
trauma resuscitation (D. Naumann et al, unpublished data). This allows comparison 
of PHBP against existing standard care. 
 
The average volume of one unit of RBC is approximately 270 ml (range: 220-340), 
while reconstituted Lyoplas N-w is 213ml. Thus one unit each of RBC and LP have a 
comparable volume to two saline boluses. 
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Delivery of interventions 
Participants receive up to four boluses of the assigned intervention to restore and 
maintain SBP≥90mmHg or a palpable radial pulse. This is assessed after each 
bolus. If SBP is restored before all intervention boluses are administered, but 
subsequently falls, interventions continue from the point at which delivery was 
paused. All interventions should be administered through fluid warmers and may be 
administered by intravenous or intraosseous route. If additional fluid is required to 
maintain blood pressure, further 250ml boluses of 0.9% saline may be given 
according to normal local practice. All other pre-hospital and in-hospital care 
proceeds as directed by the treating clinicians. 
 
Practical considerations leading to the choice of 1:1 blood product ratio 
Various factors lead to the selection of a combination of RBC and LP as the trial 
intervention. Optimum blood product ratios remain a matter of debate. The 
Prospective Observational Multicentre Major Trauma Transfusion cohort study found 
that failure to achieve plasma or platelet:RBC ratios of at least 1:2 during the first six 
hours from admission was associated with significantly higher mortality than 
amongst patients who received at least 1:1 (Holcomb et al., 2013). In contrast, the 
Pragmatic Randomized Optimal Platelet and Plasma Ratios RCT found no difference 
in overall mortality between plasma, platelets and RBCs administered in a ratio of 
1:1:1 donor units compared to 1:1:2 (Holcomb et al., 2015b). In observational 
studies, hospital-based administration of plasma within the first six units of blood 
products is associated with a 66% reduction in the odds ratio for 30-day 
mortality (del Junco et al., 2013). Pre-hospital administration of 1:1 ratios of thawed 
plasma and RBC to battlefield casualties has been associated with a 58% reduction 
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in mortality compared to historical injury-matched controls (O'Reilly et al., 2014b). 
Plasma:RBC ratios of 1:1 are perceived as offering the maximum possible benefit. 
RePHILL seeks to deliver this from as close to the time of injury as possible. 
  
Rationale for Lyophilised plasma rather than fresh frozen plasma 
Various approaches to the delivery of plasma in the field have been described. Fresh 
frozen plasma (FFP) can be carried by ground ambulance for rapid on-site 
thawing (Moore et al., 2015), but requires custom-made packaging and significant 
investment in equipment for each ambulance installation. Pre-thawed plasma is 
suitable for situations where the PHEM team deploy from a base close to the blood 
bank and where unused product can be rotated back into stock with an expectation 
use before expiry to avoid wastage. This logistic model was used by the UK Defence 
Medical Services in Afghanistan, based around a five-day post-thaw shelf-
life (O'Reilly et al., 2014a). A similar approach in a US civilian study reported less 
than 2% wastage of blood products (Holcomb et al., 2015a). UK regulations at the 
time of trial design limited the post-thaw shelf-life of FFP to 24 hours (this post-thaw 
period was extended to 5 days in 2016). UK civilian PHEM teams typically deploy by 
helicopters based at airfields remote from medical facilities. Given the relative 
infrequency of exsanguinating trauma in the UK, reliance on pre-thawed plasma 
might be unacceptably wasteful. In contrast, LP can be stored at room temperature 
for up to 15 months and reconstituted for use in as little as five minutes. Its suitability 
for the pre-hospital environment is demonstrated by the Israeli military’s decision to 
replace pre-hospital crystalloid with LP as the resuscitation fluid of choice (Glassberg 
et al., 2013). The French military utilise a French-produced LP as its sole plasma 
product on operations (Sailliol et al., 2013), while the UK Defence Medical Services 
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introduced LyoPlas N-w for remote operations in 2012 (Gokhale et al., 2016). 
Norwegian civilian helicopter emergency medical services have carried LP since 
2013 (Zielinski et al., 2017). 
 
Source of blood products  
 LyoPlas N-w is a lyophilised plasma manufactured by the German Red Cross. 
Individual units are manufactured from single donations. It is licensed in Germany 
(license PEI.H.03075.01.1) for the same indications as FFP. Approval for the import 
and use of LyoPlas N-w as an Investigational Medical Product for the purposes of 
this trial was granted by the UK Medicines and Healthcare Regulatory Authority 
(MHRA) (Clinical Trials Authorisation: 16719/0228/001-0001). 
 
The RBC used in RePHILL are blood group O, RhD negative, Kell negative, 
leucodepleted RBC in saline, adenine, glucose and mannitol (SAG-M) additive 
solution, drawn from national NHS Blood and Transplant stocks supplied by the 
blood banks that are supporting the trial. A summary of standard collection and 
processing is included as supplementary material. 
 
Regulatory Framework 
The MHRA  considers LyoPlas N-w to be a pharmaceutical, rather than a blood 
product in view of the post-donation processing (Joint UKBTS/NIBSC Professional 
Advisory Committee, 2010). RePHILL is conducted in accordance with the amended 
Clinical Trials Regulations (2004, 2006), Good Clinical Practice (International 
Conference on Harmonisation of Technical Requirements for Registration of 
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Pharmaceuticals for Human Use, 1996) and the Declaration of Helsinki (World 
Medical Association, 2013). 
 
Randomisation 
Randomisation is performed by a computer programme at the Trial Coordinating 
Centre – the Birmingham Clinical Trials Unit (BCTU). Participants are randomised at 
the level of the individual in a 1:1 ratio to either PHBP resuscitation or crystalloid 
resuscitation. The randomisation procedure is stratified by Intervention Delivery Site 
(IDS) to account for variation in type of trauma and the care provided between sites. 
 
Nominated personnel at each blood bank obtain randomised allocations via a secure 
online randomisation system (accessible 24 hours per day). Blood banks are 
supplied with pre-printed “treatment box number” labels. The allocated trial 
intervention is then packed in transport boxes, secured with tamper-proof seals and 
labelled with the specified box numbers.  
 
Pre-recruitment blinding 
Each intervention is issued in two sealed, thermally stable transport boxes 
(conditioned for the different storage requirements of RBC and LP), labelled with the 
same “treatment box number” as issued by the Trial Coordinating Centre. For 
crystalloid interventions, each box contains two 250ml 0.9% saline. For PHBP 
interventions, one container contains two units of RBCs, the other contains two units 
of LyoPlas N-w. Additional weight is added to boxes containing crystalloid to ensure 
that the intervention cannot be predicted by box weight. Sealed and numbered 
transport boxes are delivered to PHEM services by courier. These remain sealed 
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until after a decision has been made to enter a patient into the trial. Only one 
intervention is carried at a time. This removes any need for the PHEM team to 
contact the Trial Coordinating Centre during the pre-hospital phase which would both 
delay treatment and risk loss to recruitment if communications could not be 
established. 
 
To ensure that pre-recruitment blinding is maintained, the integrity of seals is subject 
to 100% audit on the return of unused interventions. This also confirms that 
interventions have been kept in the appropriate conditions and that no tampering has 
taken place. 
 
Patient Randomisation, Enrolment and Lactate Measurement 
The PHEM doctor assesses the potential participant’s vital signs on scene and 
confirms if eligible for entry into the RePHILL trial. If they fulfil the eligibility criteria, a 
capillary blood lactate concentration is measured and the treatment boxes opened. 
The randomised study intervention is revealed and given to the patient. Participants 
are considered entered into the trial when the PHEM team open the first treatment 
box. 
 
Eligibility is documented at the Receiving Hospital Site, and the participant is 
enrolled into the trial and assigned a Trial Number.  Participants who are later found 
to be ineligible, but who have received the trial interventions will remain in the trial as 
per protocol and included in the analysis, if they consent to this. 
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Venous lactate concentration is measured on arrival at ED as part of a standard 
trauma admission blood draw. A further venous lactate will be drawn two hours after 
arrival at the ED as part of RePHILL. 
 
Consent 
Legal framework for research in patients lacking capacity 
As the occurrence of major trauma is unpredictable and immediately incapacitating, 
prospective informed consent from participants is not possible. In the rare event that 
a participant retains capacity at trial entry, their clinical condition will require 
immediate resuscitation. It would be inappropriate to delay life-saving treatment and 
transport in order to seek informed consent. UK legislation permits emergency care 
research to begin in such contexts (Clinical Trials Regulations 2004 (as amended); 
Human Tissue Act 2004 (as amended))  and has been applied in the PARAMEDIC-2 
RCT of adrenaline in out-of-hospital cardiac arrest  (Perkins et al., 2015, p17). 
Details of the relevant legislation are provided as supplementary material. 
 
Consent in RePHILL 
Consent to continue in RePHILL is sought at the earliest appropriate opportunity. In 
practical terms, this consent is to continue data collection as most trial processes will 
have occurred prior to any opportunity to seek informed consent from a participant or 
appropriate representative. Initial consent is usually sought from a professional legal 
representative shortly after arrival at the receiving hospital, as it is rare for either the 
participant to retain capacity at this time, or for a personal legal representative to be 
available. As with PARAMEDIC-2, this is deemed to be at a point when the 
participant is no longer critically ill. An approach to patient or personal legal 
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representative can then be made at a time when they are better able to retain and 
consider information. 
 
The most challenging ethical consideration in this trial relates participants who die 
prior to consent being obtained. RePHILL employs a passive information approach, 
consistent with previous and ongoing emergency care studies (Perkins et al., 2015), 
placing information in locations likely to be visited by relatives of the deceased. The 
information contains a brief summary of the trial and contact details for those wishing 
further information. Further details of the rationale for this approach is provided as 
supplementary material.  
 
Jehovah's Witnesses  
Jehovah's Witnesses hold beliefs which prohibit the receipt of blood transfusions. 
Normal trauma resuscitation practice in EDs and amongst PHEM teams currently 
delivering PHBP is to search for an Advance Medical Directive (AMD), identifying a 
patient as a Jehovah’s Witness prior to the administration of blood products. 
Clinicians involved in RePHILL perform the same rigorous checks in the pre-hospital 
environment, prior to recruitment. Liaison with representatives of the Hospital Liaison 
Committees for Jehovah’s Witnesses and national Jehovah’s Witnesses Hospital 
Information Services took place during trial design and implementation to ensure that 
information regarding RePHILL was communicated to potentially affected 
communities. 
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Additional Trial Procedures and Assessments 
The standard admission blood draw on ED arrival includes full blood count, 
prothrombin time and International Normalised Ratio. Transfusion measures include 
blood grouping and assessment of mixed-field blood groups. Selected sites will also 
assess coagulation by viscoelastic methods (ROTEM™) and platelet function 
(MultiPlate™). Other assessments are summarised in Table 2. Data collection ends 
at the earliest of discharge from the acute care facility, death or 30 days, unless 
consent is withdrawn earlier. Mortality data will continue to be collected for 
participants who remain in an acute care facility beyond 30 days. 
 
Safety Considerations 
The additional risk to participants in RePHILL is considered to be minimal. As 
discussed above, “standard care” recipients receive treatment identical to that which 
they would receive outwith the trial whereas PHBP recipients receive treatment 
equivalent to that which they would receive on arrival at an ED. 
 
Transfusion safety 
The plasma from which LyoPlas N-w is produced is filtered, rendering it “virtually 
cell-free”. LyoPlas N-w is only produced from leucocyte-antibody negative plasma, 
minimising risk of transfusion-related acute lung injury (DRK-Blutspendedienst West, 
2017). LP transfusion is safe, with no reported transfusion reactions associated with 
French LP (Martinaud et al., 2011) or the previous German mini-pool LP (Schoenfeld 
et al., 2010), while the incidence of transfusion reactions associated with LyoPlas 
N-w is no different from that of FFP (Bux et al., 2013; DRK-Blutspendedienst West, 
2017). Systematic review of PHBP resuscitation for trauma identified only two 
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potential pre-hospital transfusion reactions, both associated with RBC transfusion, 
amongst 759 PHBP recipients (Smith et al., 2016). A third potential event 
(associated with LyoPlas N-w) was reported subsequently (Shlaifer et al., 2017) in a 
cohort of 109 recipients. A true transfusion reaction was considered the most likely 
explanation in only of these (associated with pre-hospital RBC transfusion). In 
contrast, UK haemovigilance monitoring reports the rate of allergic, hypotensive or 
severe febrile reactions to FFP as one per 721 units issued (Bolton-Maggs et al., 
2016). 
 
LyoPlas N-w is produced by a quarantined single donor process – plasma is only 
processed if a donor retests negative for blood-borne pathogens at least four months 
after the donation was received, thus minimising the risk of blood borne virus 
transmission (Bux et al., 2013). Based on previous national modelling (Advisory 
Committee on the Safety of Blood, 2013), transmission of prion disease (particularly 
variant Creutzfeld-Jakob Disease) is not considered a hazard of this study (for full 
discussion, see supplementary material). 
 
Transfer delay 
Delivering PHBP has the potential to incur a delay in transfer to definitive 
haemorrhage control, increasing risk to patients. This is reported as a secondary 
outcome and is one of the safety considerations to be monitored by the DMEC. 
 
Adverse Event Reporting 
Adverse events will be reported in accordance with statute (Clinical Trials 
Regulations 2004), using standard definitions of events and causality. Given the high 
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mortality and morbidity anticipated in a major trauma population, certain Serious 
Adverse Events (SAEs) are exempt from expedited reporting (Table 4). SAEs 
relating to a pre-existing condition will not be reported. 
 
The inclusion of RBC as a component of the intervention mandates compliance with 
normal haemovigilance requirements. Transfusion-related adverse events are to be 
reported to both the coordinating blood bank for the relevant IDS and via the Serious 
Hazards Of Transfusion and Serious Adverse Blood Reactions and Events 
(SHOT/SABRE) in accordance with the EU Blood Safety Directive (2005). 
 
Internal Pilot Phase 
RePHILL successfully completed an internal pilot phase to assess trial logistics, 
validate the multi-centre aspects of the trial and confirm that it was both feasible and 
practical to continue to recruit into the main trial. At the end of the pilot phase, the 
following targets were set to justify progression to the main trial: 
• Minimum of 25 participants recruited across at least two active sites; 
• In participants recruited to the trial intervention arm, at least one unit of RBC 
and one unit of LP delivered to at least 80% of participants before reaching 
hospital; 
• At least 90% data capture; 
• The Data Monitoring and Ethics Committee (DMEC) have no safety concerns 
which would prohibit continuation to the main trial. 
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Statistical Methods 
The primary comparison will be those randomised to resuscitation with PHBP versus 
those randomised to resuscitation with 0.9% saline (standard care). All primary 
analyses will be based on the intention-to-treat principle. For all major outcome 
measures, summary statistics and differences between groups (e.g. mean 
differences, relative risks, hazard ratios) will be presented with 95% confidence 
intervals (CIs) and p-values from 2-sided tests also given. Outcomes will be adjusted 
for the stratification variable, IDS, where possible. A p-value <0.05 will be considered 
statistically significant. No adjustment for multiple comparisons will be made. 
 
Primary outcome analysis 
The primary outcome is a binary composite measure of episode mortality and early 
lactate clearance. A relative risk and 95% CI will be calculated using log-binomial 
regression modelling. Individual components will also be reported in accordance with 
the recommendations of Ferreira-Gonzalez et al. (2007). 
 
Secondary outcome analysis 
Dichotomous data (e.g. development of ARDS, mortality at specified time-points) will 
be analysed in the same way as the primary outcome. Mortality will also be analysed 
using the log-rank test with a Cox Proportional Hazard model used to calculate 
hazard ratios. Continuous outcomes (e.g. pre-hospital fluid volumes, vital signs) will 
be analysed at specified time-points using linear regression models, with mean 
differences and 95% CIs reported. 
 
Subgroup analyses 
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Eleven a priori subgroup analyses are planned with respect to the primary outcome 
measure (Table 5). Tests for statistical heterogeneity (e.g. by including the treatment 
group by subgroup interaction parameter in the regression model) will be performed 
prior to any examination of effect estimates within subgroups. The results of 
subgroups will be treated with caution and will be used for the purposes of 
hypothesis generation only. 
 
Missing data and Sensitivity Analyses 
Every attempt will be made to collect full follow-up data on all study participants, it is 
thus anticipated that missing data will be minimal. Participants with missing primary 
outcome data will not be included in the primary analysis in the first instance. This 
presents a risk of bias, and sensitivity analyses will be undertaken to assess the 
possible impact of the risk. Missing responses will be simulated using a Markov 
chain Monte Carlo method (MCMC) to generate multiple datasets. Analysis will be 
then be performed on each set with the results combined using Rubin’s rule to obtain 
a single set of results (treatment effect estimate and confidence intervals). Any 
sensitivity analyses will not, irrespective of their differences, supplant the planned 
primary analyses. 
 
Data Monitoring and Ethics Committee (DMEC) 
An independent DMEC has been established to oversee the safety of participants in 
the trial. The DMEC met prior to the trial opening to enrolment and after the internal 
pilot phase to assess the safety data and advised on continuation to the main phase 
III trial. The DMEC will now meet at least annually. Interim analyses of major 
outcome measures and safety data will be conducted and provided in strict 
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confidence to the DMEC, which will consider whether the accumulated data from the 
trial, together with the results from other relevant research, justifies continued 
recruitment of further participants. The DMEC operates in accordance with a trial 
specific charter. 
 
Dissemination 
The trial results will be reported in accordance with the CONSORT 
guidelines (Schulz et al., 2011) and will be submitted for publication in peer-reviewed 
journals and presentation at appropriate national and international academic 
meetings. Trial participants will be sent a summary of the final results, including 
references to full papers. RePHILL data may be made available to external groups 
wishing to undertake original analysis, subject to approval from the Trial 
Management Group. 
 
DISCUSSION 
 
Early blood product transfusion and reduced crystalloid administration has been 
associated with improved survival in observational, predominantly retrospective, 
military and civilian studies (Bhangu et al., 2013; Murad et al., 2010; Rajasekhar et 
al., 2011). Projection of blood products into the pre-hospital phase of trauma care is 
intuitively attractive; however the use of PHBP is both logistically challenging and 
resource intensive, and is not without risk (Bolton-Maggs, 2015). The most 
significant and immediate risk of ABO incompatibility may be managed by use of 
“universal components”. This, however, has implications for resource management. 
Although “universal” plasma donors (group AB) constitute only 4% of the UK donor 
pool (NHS Blood and Transplant, 2014), low anti-B titre group A pre-thawed FFP is 
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more available and is an established source of emergency plasma transfusions in 
patients of unknown ABO group in North American Trauma Centres (Dunbar et al., 
2016). The success and safety of this approach has been reflected in recently 
published UK guidelines (Hunt et al., 2015). However, this represents a logistical 
challenge for helicopter-based services which frequently deploy from airfields remote 
from the blood banks that support them. Alternative forms of plasma with longer 
shelf-lives need to be considered, such as the LP used in RePHILL. In addition, 
provision of an adequate supply of “universal” group O RhD negative red cell 
concentrates (drawn from only 8% of the UK donor pool) remains challenging. Group 
O RhD negative, Kell negative red cell concentrates should ideally be reserved for 
female recipients of child bearing age (Hunt et al., 2015). Such resource 
management is impractical in the pre-hospital environment due to the constraints on 
space and weight inherent in helicopter-based service. Hypothetically, early 
“haemostatic” resuscitation might reduce overall transfusion requirements, thus 
preserving blood products stocks. However, no such benefit has been demonstrated 
to date (Smith et al., 2016). 
 
A convincing case for PHBP that justifies utilisation of scarce universal donor 
resources cannot be made from the published literature, with only “low” and “very 
low” quality evidence, derived from entirely observational studies (predominantly 
retrospective case series) (Smith et al., 2016). More recent retrospective military 
data found an association between a directive mandating pre-hospital helicopter 
evacuation of critically injured battlefield casualties within 60 minutes of wounding 
and a reduction in mortality (Kotwal et al., 2016). One component of this may have 
been the delivery of PHBP. However, in common with the majority of studies in this 
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field, missing data and potential confounding was such that the “influence on 
morbidity and mortality could not be reliably measured”.  
 
Experts in the field have called for “prospective studies…to clarify the role of [freeze-
dried plasmas] and RBCs in civilian prehospital hemorrhagic shock 
resuscitation” (Sunde et al., 2015) and have stressed the importance of “high-quality 
prospective…data collection” (Jenkins et al., 2014b). A prospective observational 
study recently reported no evidence of superiority of PHBP in reducing mortality, but 
was limited by significant differences in trauma burden and physiology between 
patients retrieved by PHBP-capable services compared to those transported without 
access to PHBP (Holcomb et al., 2017). The authors concluded that “large, 
multicentre randomized studies [are] required”.  
 
Five PHBP RCTs have attempted to meet this need. Two have terminated 
early (Shackelford, 2017) due to futility (Control Of Major Bleeding After Trauma - 
COMBAT) (Moore et al., 2015) or insufficient recruitment (Pre-Hospital Use of 
Plasma for Traumatic Hemorrhage - PUPTH) (Reynolds et al., 2015). Other than 
RePHILL, ongoing studies include the Prehospital Air Medical Plasma study 
(PAMPer) (Brown et al., 2015a) and the Pre-hospital Administration of Lyophilized 
Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO) (Jost and 
Lanoe, 2017). PAMPer compares two units of thawed plasma against standard care 
in a US trauma population and aims to recruit 530 patients. PREHO-PLYO is a 
smaller French study of 140 patients investigating the effect of lyophilised plasma on 
coagulation. The study size calculations for RePHILL and PAMPer are broadly 
similar. However, PAMPer seeks to detect a 67% relative reduction from a baseline 
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of 22% 30-day mortality, whereas RePHILL’s inclusion of a measure of resuscitation 
efficacy in the composite primary outcome allows assessment of a more modest 
treatment effect with greater focus on that part of the patient’s trauma journey most 
likely to be affected by pre-hospital intervention. In addition, mechanisms of injury 
differ between the USA and UK; PAMPer is likely to recruit a higher proportion of 
penetrating trauma victims whereas a preponderance of blunt trauma is anticipated 
amongst RePHILL participants. Thus PAMPer and RePHILL are complementary 
studies that have the potential to increase knowledge of the response to trauma 
resuscitation across a spectrum of injury. 
 
CONCLUSIONS 
 
RePHILL provides a timely and unique opportunity to generate high quality evidence 
regarding the efficacy of PHBP resuscitation for trauma patients. Patient-centred 
outcome measures include survival and morbidity. Physiological and coagulation 
studies will add to understanding of the mechanisms underlying trauma 
resuscitation. Logistic considerations will aid future service planning if a benefit to 
patients is demonstrated.  
 
The RePHILL trial opened to recruitment in December 2016. In June 2017, the 
funder (NIHR Efficacy and Mechanism Evaluation) confirmed successful completion 
of the pilot phase and agreed that the trial could progress into the main Phase III 
RCT. As of 01 August 2017, 34 patients had been recruited into the trial.  
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Study Documents, Administration, Funding and Registration 
The full trial Protocol and related documents are available at: 
www.birmingham.ac.uk/rephill  
 
Trial Registration 
ISRCTN registry identifier: ISRCTN62326938, assigned 11 July 2016 
EudraCT registration: 2015-001401-13 
MHRA Clinical Trials Authorisation: 16719/0228/001-0001 
 
Research Ethics Committee Approval: South Central - Oxford C, ref: 15/SC/0691 
 
Funding: The RePHILL Trial is supported by the National Institute for Health 
Research Efficacy and Mechanism Evaluation Programme, grant number 14/152/14. 
GDP is supported as a NIHR Senior Investigator and Director of Research for the 
Intensive Care Foundation 
 
Sponsor: University Hospitals Birmingham NHS Foundation Trust (RRK5174) 
The Sponsor and Funder provided feedback during study design. The RePHILL Trial 
Collaborators are responsible for study design and for data collection, processing, 
analysis and interpretation. The decision to submit the final report lies exclusively 
with the Trial Management Group. 
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Midlands Air Ambulance 
Warwickshire & Northamptonshire Air Ambulance 
 
Essex Voluntary Blood Service 
Leicestershire & Rutland Blood Bikes 
Midlands Freewheelers 
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SERV Suffolk & Cambridge 
Warwickshire & Solihull Blood Bikes 
 
East of England Ambulance Service NHS Trust 
West Midlands Ambulance Service NHS Foundation Trust 
 
Barts Health NHS Trust 
Cambridge University Hospitals NHS Foundation Trust  
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